Studies have shown that integrating anlotinib with programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors enhances survival rates among progressive non-small-cell lung cancer (NSCLC) patients lacking driver...
Read More
The following is a summary of “Impact of Baseline Interstitial Lung Abnormalities on Pneumonitis...
Read More
The following is a summary of “Safety and Efficacy of Immune Checkpoint Inhibitors in Cancer...
Read MoreLung cancer is the second most common cancer worldwide, with non-small-cell lung cancer (NSCLC) accounting for the majority of cases. Patients with NSCLC have achieved great survival benefits from immunotherapies targeting...
Read MoreTargeted anti-programmed death receptor 1 (PD-1) monoclonal antibodies, when combined with chemotherapy, have shown improved outcomes in non-small cell lung cancer (NSCLC). However, it is important to note that not all patients...
Read More
The optimal primary site treatment modality for non-small-cell lung cancer (NSCLC) with brain...
Read More
Neurogenic differentiation factor 1 (NEUROD1) is frequently overexpressed in small-cell lung...
Read MoreThis study evaluated the association between elevated C-reactive protein (CRP) and clinical outcomes among adults treated with surgery for non-small cell lung cancer (NSCLC) in the US.Adults with NSCLC who underwent lung cancer...
Read More
Small-cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options. The...
Read More
Biological response modifiers (immunotherapy) in combination to chemotherapy are superior to that...
Read More
Prehabilitation has been shown to increase survival rates after cancer operations. When...
Read MoreIn the NADIM trial, neoadjuvant chemotherapy combined with nivolumab was successful in treating resectable non-small-cell lung cancer (NSCLC). The investigation of the circulating tumor DNA (ctDNA) and 3-year overall survival...
Read More
Patients with stage III non-small-cell lung cancer that was unresectable and who were still alive...
Read More
Concurrent chemoradiotherapy (CCRT) and adjuvant durvalumab are the recommended treatments for...
Read More
For a study, researchers sought to determine how long postponing therapy for stage III-IV...
Read More
For a study, researchers sought to look at non-small-cell lung cancer patients who received...
Read More
Despite the limited sample size of studies, the low occurrence rate of these changes necessitates...
Read More
The IMpower trials reported significant effects of atezolizumab-containing chemotherapies on...
Read More
Segmentectomy has been reported as an alternative to lobectomy for small-sized NSCLC without...
Read More
There is lack of consensus whether neoadjuvant chemoradiotherapy (CHT/RT) is superior to...
Read More
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
